newsfilter
← Latest News
GlobeNewswire·

James M. O'Brien Appointed Chief Financial Officer at Mesoblast

NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that in connection with the Company's